Tirzepatide obesity prescribing moved into the GP contract
From 1 April, prescribing of tirzepatide for obesity was incorporated into the 2026/27 GP contract through new Quality and Outcomes Framework indicators. Participation by practices is optional, so meeting the eligibility criteria does not guarantee access, and availability varies by area.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.